The purpose of this proposal is to continue to study the mechanism of cellular immunity and hypersensitivity with the hope of finding ways to modulate this immune response in relevant clinical states. The focus is on lymphokines that alter the behavior of macrophages and activate them. We propose: to obtain purified and characterized lymphokines using T-T cell hybrids and recombinant DNA technology; to study the basis for heterogeneity of lymphokines and their interrelationship; to characterize the macrophage receptors for these; and to study the cellular and genetic changes associated with alteration of macrophage function by lymphokines. The projects to attain these goals are: 1) Continue to generate a series of human T-T cell hybrids which secrete MIF and MAF and to purify and characterize these. In addition, generate monoclonal antibodies to MIF and MAF and develop an improved assay for human MAF. 2) Further studies on the macrophage activating factor which enhances anti-viral activity in human macrophages and which has no interferon activity, and study a lymphokine which induces leucotriene production in human macrophages. 3) Examination of the basis and biological significance of the heterogeneity of MIF and MAF induced by antigens such as bacteria, fungi and viruses, and the production of lymphokines by different subsets of lymphocytes. 4) Identification of genes coding for MIF and MAF, the characteristics of these genes and the production of recombinant MIF and MAF. 5) Further studies on the human macrophage receptor for MIF: characterization, binding kinetics and biology, and the analysis of the fate of the labeled receptor and ligand by light and electron microscopy. 6) HL60 cells as a model for macrophage response to MIF. The addition of the MIF glycolipid receptor to these cells makes them responsive to MIF. The molecular events that follow stimulation by the lymphokine will be analyzed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI022532-04
Application #
3133725
Study Section
Immunobiology Study Section (IMB)
Project Start
1985-01-01
Project End
1992-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Satoskar, A R; Bozza, M; Rodriguez Sosa, M et al. (2001) Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun 69:906-11
Satoskar, A R; Rodig, S; Telford 3rd, S R et al. (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30:834-9
Bozza, M; Satoskar, A R; Lin, G et al. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-6
Ochi, H; Hirani, W M; Yuan, Q et al. (1999) T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190:267-80
Satoskar, A R; Stamm, L M; Zhang, X et al. (1999) Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection. J Immunol 162:6747-54
Stamm, L M; Satoskar, A A; Ghosh, S K et al. (1999) STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol 29:2524-9
Soares, M B; Titus, R G; Shoemaker, C B et al. (1998) The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. J Immunol 160:1811-6
Bozza, M; Soares, M B; Bozza, P T et al. (1998) The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol 28:3120-7
Stamm, L M; Raisanen-Sokolowski, A; Okano, M et al. (1998) Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol 161:6180-8
Soares, M B; David, J R; Titus, R G (1997) An in vitro model for infection with Leishmania major that mimics the immune response in mice. Infect Immun 65:2837-45

Showing the most recent 10 out of 45 publications